Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics - CHINOOK

Study identifier:D3250C00059

ClinicalTrials.gov identifier:NCT03953300

EudraCT identifier:2018-003391-13

CTIS identifier:2023-506614-40-00

Recruiting

Official Title

A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

81

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 17 Oct 2019
Estimated Primary Completion Date: 09 Sept 2026
Estimated Study Completion Date: 09 Sept 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria